Search the Newsreel

Mistras Group (MG) investor Aspasia Vahaviolos discloses 19.2% ownership stake

Aspasia Vahaviolos has disclosed a 19.2% ownership stake in Mistras Group (MG) through a Schedule 13G/A filing. Her holdings consist of 6,105,650 shares, including 1,794,839 shares held directly and 4,310,811 shares in a grantor retained annuity trust managed by her daughter. This significant stake …

What is HC Wainwright's Estimate for MIST FY2028 Earnings?

Milestone Pharmaceuticals Releases Q2 2026 Financial Results

Milestone Pharmaceuticals Inc. reported a wider net loss of $28.6 million for Q2 2026, with a loss of $0.21 per share on revenue of $559,000. This was attributed to continued investment in commercializing its cardiovascular medicines. Despite the current losses, analysts maintain confidence with …

Milestone Pharmaceuticals Inc. Q2 2026 Earnings Call Summary

Mistras: My Little Stock Pick Grew Up (NYSE:MG)

Mistras Group, Inc. (MG) has delivered strong results, driven by successful diversification and execution of its "Vision 2030." The company raised its full-year revenue and adjusted EBITDA guidance, reflecting accelerated growth and improved profitability. The author reiterates a Buy rating with a $26 price …

Milestone Pharmaceuticals Inc (MIST) Stock Forecast, Price Targets and Analysts Predictions

This article from GuruFocus provides a stock forecast and analyst predictions for Milestone Pharmaceuticals Inc (MIST). It details the company's current stock price, market capitalization, enterprise value, and GF Score. The article also mentions that price targets and analyst ratings are available to subscribers.

Mistras Group Releases Q2 2026 Financial Results

Mistras Group, Inc. reported stronger-than-expected Q2 2026 financial results, with non-GAAP earnings per share of $0.28, surpassing Wall Street estimates by 16.7%. The company achieved $193.1 million in revenue, a 4.2% increase year-over-year, driven primarily by its Oil & Gas segment. Analysts maintain a …

Milestone Pharmaceuticals (NASDAQ:MIST) Releases Earnings Results, Misses Expectations By $0.01 EPS

Milestone Pharmaceuticals (NASDAQ:MIST) reported its latest earnings, missing analyst expectations with a loss of $0.21 per share against an anticipated $0.20 loss, and revenues of $0.56 million compared to an expected $0.82 million. Despite the wider net loss of $28.6 million due to increased …

Earnings call transcript: Milestone posts Q2 loss as CARDAMYST launch gains traction

Milestone Pharmaceuticals reported a wider-than-expected Q2 2026 loss of $0.21 per share, despite exceeding revenue forecasts with $559 million, driven by early commercial traction for its new heart-rhythm drug CARDAMYST. Shares dropped over 10% in premarket trading. The company is strategically expanding commercial coverage …

Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals shares tumble after Q2 earnings miss

Milestone Pharmaceuticals (NASDAQ:MIST) saw its shares drop by 12.60% after reporting a wider-than-expected Q2 loss, despite increased prescriptions and insurance coverage for its new drug CARDAMYST. The company recorded an adjusted loss of $0.21 per share against an estimated $0.19, with a net loss …

Milestone Pharmaceuticals earnings missed by $0.02, revenue topped estimates

Milestone Pharmaceuticals (NASDAQ: MIST) reported second-quarter earnings per share (EPS) of $-0.210, missing analyst estimates by $0.02. However, the company's revenue for the quarter came in at $559 million, significantly exceeding the consensus estimate of $1.01 million. The stock has seen a decline of …

Milestone Pharmaceuticals stock tumbles 12% on Q2 earnings miss

Milestone Pharmaceuticals (NASDAQ:MIST) saw its shares drop by 12.60% after reporting a wider-than-expected Q2 loss, despite increased prescriptions and insurance coverage for its new drug CARDAMYST. The company recorded an adjusted loss of $0.21 per share against an estimated $0.19, with a net loss …

Milestone Pharmaceuticals: Q2 Earnings Snapshot

Form 8K MILESTONE PHARMACEUTICALS INC. For: 12 August By Investing.com

The article reports on a Form 8K filing by MILESTONE PHARMACEUTICALS INC. on August 12. It provides no further details on the content of the filing but lists the company's stock symbol as MIST, which saw an 8.27% decrease. The piece is primarily a …

Milestone Pharmaceuticals Inc. Q2 2026: Revenue $0.6M, EPS $(0.21) — 10-Q Summary

Milestone Pharmaceuticals Inc. reported its Q2 2026 results, showing initial product revenue of $0.6M following the U.S. launch of CARDAMYST (etripamil). The company recorded a net loss of $(28.6)M, leading to a basic and diluted net loss per share of $(0.21), which is a …

CARDAMYST now covered for over 50% of U.S. commercially insured lives

Milestone Pharmaceuticals (MIST) announced its Q2 2026 financial results, reporting a net loss of $28.6 million but significant progress for its CARDAMYST nasal spray. Commercial coverage for CARDAMYST has expanded to over 50% of commercially insured U.S. lives, and the company has seen strong …

Renaissance Technologies LLC Sells 81,100 Shares of Mistras Group Inc $MG

Renaissance Technologies LLC reduced its stake in Mistras Group Inc. by 40.2% during the first quarter, selling 81,100 shares and retaining 120,500 shares valued at $1.78 million. The technology company's shares are trading near their 52-week high after an 18.1% increase, and it recently …

Mistras Group (MG) Stock Climbs On Record EBITDA And Higher Outlook

Mistras Group's stock (MG) surged 17.7% after the company announced strong Q2 2026 results, including record adjusted EBITDA of US$25.8 million and a 4.2% increase in revenue to US$193.1 million. The company also raised its full-year revenue and profit guidance, driven by growth in …

Mistras Group Q2 2026 Deep Dive: EPS Beats Estimates, Revenue Up 4%

Is MISTRAS Group Inc (MG) Overvalued After Q2 Earnings Miss? GF Score: 66/100

MISTRAS Group Inc (MG) reported Q2 2026 revenues of $193.1 million, a 4.2% increase year-over-year, and EPS of $0.23, slightly missing analyst estimates. Despite revenue growth driven by Infrastructure, Power Generation, and Aerospace & Defense sectors, the company faces challenges in the volatile Oil …

Earnings call transcript: Mistras Group tops Q2 2026 estimates, shares jump

Mistras Group reported stronger-than-expected Q2 2026 results, with adjusted EPS of $0.28 and revenue of $193.1 million, exceeding analyst estimates. The company's stock surged 16.6% in after-hours trading after it raised its full-year guidance for both revenue and adjusted EBITDA. This performance was driven …

Mistras Group (NYSE:MG) Shares Gap Up Following Earnings Beat

Mistras Group (NYSE:MG) shares surged after reporting better-than-expected quarterly earnings, with the stock gapping up to $17.24 and last trading at $18.32. The company exceeded consensus estimates, posting earnings per share of $0.28 on revenue of $193.13 million. Analysts generally hold a "Hold" rating …

Mistras Group, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:MG) 2026-08-11

Mistras Group, Inc. published its Q2 2026 earnings call presentation, detailing its financial results for the quarter. The company reported an EPS of $0.28, beating estimates by $0.03, and revenue of $193.13 million, exceeding expectations by $3.81 million with a 4.17% year-over-year increase. This …

MISTRAS Group Inc. Q2 Profit Rises

(RTTNews) - MISTRAS Group Inc. (MG) released earnings for its second quarter that Increases, from the same period last year The company's bottom line came in at $7.58 million, or $0.23 per share. This compares with $3.02 million, or $0.10 per share, last year. …

MISTRAS Group raises FY26 sales guidance above estimates

MISTRAS Group has increased its fiscal year 2026 sales guidance to $740 million-$755 million, up from the previous range of $730 million-$750 million. This revised outlook surpasses the consensus estimate of $746.024 million, signaling strong demand for its industrial services and improved operational visibility. …

Mistras Group Reports Increased Revenue and Net Income in Q2 2026

Mistras Group, Inc. has reported increased revenue and net income for the second quarter and first six months of 2026, as detailed in its Form 10-Q filing with the Securities and Exchange Commission on August 10, 2026. This positive financial performance indicates growth compared …

Mistras Group, Inc. 2026: Revenue $193.13M, EPS $0.23— 10-Q Summary

Mistras Group, Inc. reported strong second-quarter 2026 results with revenue of $193.13M, a 4.2% increase year-over-year, and diluted EPS of $0.23, up 130%. The growth was primarily driven by strength in North America, particularly in Integrated Field Solutions and laboratory work, alongside improvements in …

MISTRAS Group Reports Second-Quarter 2026 Revenue Growth, Higher Profitability and Raised Full-Year Guidance

MISTRAS Group, Inc. reported strong Q2 2026 financial results with a 4.2% revenue increase to $193.1 million, improved gross profit margins, and a GAAP net income of $7.6 million. The company also announced a 7.0% increase in Adjusted EBITDA to $25.8 million and raised …

Mistras: Q2 Earnings Snapshot

Form 8K Mistras Group Inc For: 10 August By Investing.com

This article reports that Mistras Group Inc. filed a Form 8K on August 10th. The filing is brief and does not provide further details within the article content.

Mistras Group (NYSE: MG) lifts H1 2026 profit and extends credit facility

MISTRAS Q2 Revenue Rises 4.2% to $193.1 Million